Evidence map›Paper›PMID 34013402›Full record

ArticleAnalytical and bioanalytical chemistry2021

Heterogeneity of SARS-CoV-2 virus produced in cell culture revealed by shotgun proteomics and supported by genome sequencing.

Fabrice Gallais, Olivier Pible, Jean-Charles Gaillard, Stéphanie Debroas, Hélène Batina, Sylvie Ruat, Florian Sandron, Damien Delafoy, Zuzana Gerber, Robert Olaso and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Fabrice GallaisDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE SPI, 30200, Bagnols-sur-Cèze, France.
Olivier PibleDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE SPI, 30200, Bagnols-sur-Cèze, France.
Jean-Charles GaillardDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE SPI, 30200, Bagnols-sur-Cèze, France.
Stéphanie DebroasDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE SPI, 30200, Bagnols-sur-Cèze, France.
Hélène BatinaDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE SPI, 30200, Bagnols-sur-Cèze, France.
Sylvie RuatDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE SPI, 30200, Bagnols-sur-Cèze, France.
Florian SandronCentre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 91057, Evry, France.
Damien DelafoyCentre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 91057, Evry, France.
Zuzana GerberCentre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 91057, Evry, France.
Robert OlasoCentre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 91057, Evry, France.
Fabienne GasDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE SPI, 30200, Bagnols-sur-Cèze, France.
Laurent BellangerDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE SPI, 30200, Bagnols-sur-Cèze, France.
Jean-François DeleuzeCentre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 91057, Evry, France.
Lucia GrengaDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE SPI, 30200, Bagnols-sur-Cèze, France.
Jean ArmengaudDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE SPI, 30200, Bagnols-sur-Cèze, France. jean.armengaud@cea.fr.
CEA Paris-Saclay · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRUniversité Paris-Saclay · FRCentre National de Recherche en Génomique Humaine · FRInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FRTechnologies pour la Santé · FR

Funding

Agence Nationale de la Recherche ANR-17-CE18-0023-01
6 · The paper itself

Abstract

COVID-19 is the most disturbing pandemic of the past hundred years. Its causative agent, the SARS-CoV-2 virus, has been the subject of an unprecedented investigation to characterize its molecular structure and intimate functioning. While markers for its detection have been proposed and several diagnostic methodologies developed, its propensity to evolve and evade diagnostic tools and the immune response is of great concern. The recent spread of new variants with increased infectivity requires even more attention. Here, we document how shotgun proteomics can be useful for rapidly monitoring the evolution of the SARS-CoV-2 virus. We evaluated the heterogeneity of purified SARS-CoV-2 virus obtained after culturing in the Vero E6 cell line. We found that cell culture induces significant changes that are translated at the protein level, such changes being detectable by tandem mass spectrometry. Production of viral particles requires careful quality control which can be easily performed by shotgun proteomics. Although considered relatively stable so far, the SARS-CoV-2 genome turns out to be prone to frequent variations. Therefore, the sequencing of SARS-CoV-2 variants from patients reporting only the consensus genome after its amplification would deserve more attention and could benefit from more in-depth analysis of low level but crystal-clear signals, as well as complementary and rapid analysis by shotgun proteomics.

Indexed as

Genome, ViralAmino Acid SequenceCell Culture TechniquesHumansProteomicsReal-Time Polymerase Chain ReactionSARS-CoV-2Tandem Mass SpectrometryViral ProteinsVirulenceViral ProteinsGenome sequencingMass spectrometryMutationsSARS-CoV-2VariantsViral particles

Identifiers

PMID34013402
PMCPMC8134822
OpenAlexW3160621935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.